Find Orforglipron Calcium Hydrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2212020-52-3, Ly3502970, Chembl4446782, Ly-3502970, 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one, 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one
Molecular Formula
C48H48F2N10O5
Molecular Weight
883.0  g/mol
InChI Key
USUWIEBBBWHKNI-KHIFEHGGSA-N
FDA UNII
7ZW40D021M

Orforglipron Calcium Hydrate
1 2D Structure

Orforglipron Calcium Hydrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one
2.1.2 InChI
InChI=1S/C48H48F2N10O5/c1-25-18-32(19-26(2)40(25)49)60-42(58-16-15-57(46(58)63)37-11-10-36-33(41(37)50)24-51-55(36)7)39-28(4)56(14-12-34(39)53-60)43(61)38-21-31-20-29(30-13-17-64-47(5,6)23-30)8-9-35(31)59(38)48(22-27(48)3)44-52-45(62)65-54-44/h8-11,15-16,18-21,24,27-28,30H,12-14,17,22-23H2,1-7H3,(H,52,54,62)/t27-,28-,30-,48-/m0/s1
2.1.3 InChI Key
USUWIEBBBWHKNI-KHIFEHGGSA-N
2.1.4 Canonical SMILES
CC1CC1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)C5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7C6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
2.1.5 Isomeric SMILES
C[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7[C@@H]6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
2.2 Other Identifiers
2.2.1 UNII
7ZW40D021M
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ly3502970

2.3.2 Depositor-Supplied Synonyms

1. 2212020-52-3

2. Ly3502970

3. Chembl4446782

4. Ly-3502970

5. 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one

6. 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one

7. V6g

8. Orforglipron [inn]

9. Orforglipron [usan]

10. Ly3502970 (orforglipron)

11. Owl833

12. Schembl21175277

13. Gtpl12175

14. 7zw40d021m

15. Ex-a7751

16. Bdbm50514045

17. Akos040733262

18. Glp-1 Receptor Agonist 1;orforglipron

19. Ms-31635

20. Hy-112185

21. Cs-0043632

22. 1,2,4-oxadiazol-5(2h)-one, 3-[(1s,2s)-1-[2-[[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2,3-dihydro-2-oxo-1h-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5h-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4s)-tetrahydro-2,2-dimethyl-2h-pyran-4-yl]-1h-indol-1-yl]-2-methylcyclopropyl]-

23. 3-[(1s,2s)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4s)-2,2-dimethyloxan-4-yl]-1h-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5h)-ide

2.4 Create Date
2019-01-28
3 Chemical and Physical Properties
Molecular Weight 883.0 g/mol
Molecular Formula C48H48F2N10O5
XLogP36.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area144
Heavy Atom Count65
Formal Charge0
Complexity1950
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Fujian Genohope Biotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

02

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Transo Pharm USA Company Banner

03

Shandong Chenghui Shuangda Pharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Chenghui Shuangda Pharmaceutical

04

Jiangsu Sinopep Allsino Biopharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

KY/TN Water Professionals
Not Confirmed
arrow

Jiangsu Sinopep Allsino Biopharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
KY/TN Water Professionals
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Hefei Home Sunshine Pharmaceutical...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

KY/TN Water Professionals
Not Confirmed
arrow

Hefei Home Sunshine Pharmaceutical...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
KY/TN Water Professionals
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Nantong Quanyi Biotechnology

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

KY/TN Water Professionals
Not Confirmed
arrow

Nantong Quanyi Biotechnology

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
KY/TN Water Professionals
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

KY/TN Water Professionals
Not Confirmed
arrow

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
KY/TN Water Professionals
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Sichuan Taienkang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

KY/TN Water Professionals
Not Confirmed
arrow

Sichuan Taienkang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
KY/TN Water Professionals
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

KY/TN Water Professionals
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
KY/TN Water Professionals
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

KY/TN Water Professionals
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
KY/TN Water Professionals
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

KY/TN Water Professionals
Not Confirmed

01

KY/TN Water Professionals
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41815

Submission : 2025-04-27

Status : Active

Type : II

blank

02

Allsino Pharmaceutical Co Ltd

Country

USDMF

arrow
KY/TN Water Professionals
Not Confirmed

02

Allsino Pharmaceutical Co Ltd

Country
arrow
KY/TN Water Professionals
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41884

Submission : 2025-05-29

Status : Active

Type : II

blank

03

Ningxia Labschem Co Ltd

Country

USDMF

arrow
KY/TN Water Professionals
Not Confirmed

03

Ningxia Labschem Co Ltd

Country
arrow
KY/TN Water Professionals
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42012

Submission : 2025-05-26

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

Eli Lilly Kinsale Limited

Country
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

Eli Lilly Kinsale Limited

Country
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

ORFORGLIPRON CALCIUM

NDC Package Code : 63419-0603

Start Marketing Date : 2024-12-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Fujian Genohope Biotech Ltd.

Country
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

Fujian Genohope Biotech Ltd.

Country
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

ORFORGLIPRON

NDC Package Code : 84502-107

Start Marketing Date : 2025-06-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

LY3502970 (orforglipron hemicalcium hydrate) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.


Lead Product(s): Orforglipron Calcium Hydrate

Therapeutic Area: Endocrinology Brand Name: LY3502970

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 17, 2025

blank

01

Eli Lilly

U.S.A
arrow
KY/TN Water Professionals
Not Confirmed

Eli Lilly

U.S.A
arrow
KY/TN Water Professionals
Not Confirmed

Details : LY3502970 (orforglipron hemicalcium hydrate) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.

Product Name : LY3502970

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

April 17, 2025

blank

Details:

LY3502970 (orforglipron) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.


Lead Product(s): Orforglipron Calcium Hydrate

Therapeutic Area: Endocrinology Brand Name: LY3502970

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Chugai Pharmaceutical

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 28, 2023

blank

02

Eli Lilly

U.S.A
arrow
KY/TN Water Professionals
Not Confirmed

Eli Lilly

U.S.A
arrow
KY/TN Water Professionals
Not Confirmed

Details : LY3502970 (orforglipron) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.

Product Name : LY3502970

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 28, 2023

blank

Details:

LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.


Lead Product(s): Orforglipron Calcium Hydrate

Therapeutic Area: Nutrition and Weight Loss Brand Name: LY3502970

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Chugai Pharmaceutical

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 23, 2023

blank

03

Eli Lilly

U.S.A
arrow
KY/TN Water Professionals
Not Confirmed

Eli Lilly

U.S.A
arrow
KY/TN Water Professionals
Not Confirmed

Details : LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.

Product Name : LY3502970

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 23, 2023

blank

Details:

LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.


Lead Product(s): Orforglipron Calcium Hydrate

Therapeutic Area: Nutrition and Weight Loss Brand Name: LY3502970

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Chugai Pharmaceutical

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 20, 2023

blank

04

Eli Lilly

U.S.A
arrow
KY/TN Water Professionals
Not Confirmed

Eli Lilly

U.S.A
arrow
KY/TN Water Professionals
Not Confirmed

Details : LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.

Product Name : LY3502970

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 20, 2023

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

STOCK RECAP #PipelineProspector

read-more
read-more
Pipeline Prospector April 2025: Merck KGaA buys SpringWorks for US$ 3.9 bn; Swiss giants lead pharma migration to US soil
April witnessed considerable volatility in pharmaceutical stocks as the US President Donald Trump’s administration signaled major shifts in drug pricing policies and import regulations. These include Trump’s proposed international reference pricing to align US drug prices with lower costs in other developed countries, a national security investigation into pharmaceutical imports that could lead to tariffs of 25 percent or more on foreign-made drugs and, a sweeping executive order to reshape Medicare drug pricing. However, as the month drew to a close, key pharmaceutical indices rebounded and were back in the black. The Nasdaq Biotechnology Index (NBI) rose 0.44 percent from 4,241.91 to 4,260.42. The SPDR S&P Biotech ETF (XBI) rose 2.58 percent — from 80.86 to 82.95. And the S&P Biotechnology Select Industry Index (SPSIBI) increased 0.91 percent — from 6,319.47 to 6,376.95. However, stocks of most drugmakers ended the month in the red.  Access the Pipeline Prospector Dashboard for April 2025 Newsmakers (Free Excel) Trump’s tariff threats prompt drug majors to announce investments in US The unrest created by Trump’s tariff threat on drug imports was palpable across the world. In Europe, CEOs of nearly three dozen global drugmakers, including Pfizer, Eli Lilly, and AstraZeneca, warned European Commission President Ursula von der Leyen that without "rapid, radical policy change", over US$ 100 billion in pharma R&D and manufacturing could leave the European Union. These drugmakers are pushing for abandonment of price controls to match US pricing levels.  Global players are also rapidly reorienting their manufacturing strategies towards the US soil in order to avoid imminent tariffs on imported medicines. For instance, Swiss pharmaceutical giant Roche has announced a massive US$ 50 billion investment in the US over the next five years. Another Swiss drugmaker, Novartis, has committed US$ 23 billion to expand its US operations over the next five years. Meanwhile, AstraZeneca has said it will be shifting the production of some drugs sold in America from Europe to the US in order to avoid Trump’s tariffs. Even American drugmaker AbbVie plans to invest US$ 10 billion in US manufacturing over the next decade to avoid tariffs. Regeneron Pharmaceuticals has taken a different approach by announcing an investment exceeding US$ 3 billion through a 10-year strategic partnership with Fujifilm Diosynth Biotechnologies. This collaboration aims to nearly double Regeneron’s US production capacity for biologic medicines.  Access the Pipeline Prospector Dashboard for April 2025 Newsmakers (Free Excel)  Merck buys SpringWorks for US$ 3.9 bn; GSK inks US$ 2.7 bn deal with ABL Bio This was going to be a year of mergers and acquisitions. But with the imminent policy changes in America’s healthcare sector, M&A activity appears to have slowed down. However, the last days of April saw two M&A announcements — Merck KGaA entered into a deal to buy US biotech company SpringWorks Therapeutics for US$ 3.9 billion, and Novartis announced the acquisition of Regulus Therapeutics for up to US$ 1.7 billion. The month saw several licensing deals. GSK signed a licensing agreement valued at approximately £ 2.08 billion (US$ 2.66 billion) with South Korea’s ABL Bio for exclusive access to ABL’s innovative Grabody-B brain delivery platform, a technology designed to enhance the penetration of therapeutic antibodies across the notoriously selective blood-brain barrier (BBB). The BBB acts as the body’s natural defense to protect the brain from toxins and pathogens. Similarly, Eli Lilly inked a US$ 1.4 billion licensing agreement with Sangamo Therapeutics to gain access to Sangamo’s proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has shown remarkable potential in crossing the BBB. In the autoimmune and immunology space, Sanofi signed an exclusive licensing agreement with US biotech Earendil Labs valued at up to US$ 1.8 billion. The agreement centers on two next-generation bispecific antibodies, HXN-1002 and HXN-1003, discovered through Earendil's AI-driven high-throughput protein modeling platform.  Access the Pipeline Prospector Dashboard for April 2025 Newsmakers (Free Excel)  Lilly’s obesity pill matches Ozempic in trial; Novo seeks FDA nod for semaglutide pill In the market for obesity meds, Eli Lilly’s experimental weight-loss pill, orforglipron, demonstrated efficacy that was comparable to its rival Novo Nordisk’s injectable Ozempic. Analysts view orforglipron pill as a potential game-changer in obesity treatment. Meanwhile, Novo Nordisk has sought FDA approval for a 25-mg pill version of its weight loss medication semaglutide. And Rhythm Pharmaceuticals’ drug, Imcivree (setmelanotide), achieved primary endpoint in a late-stage trial for acquired hypothalamic obesity, a rare condition resulting from damage to the brain’s hypothalamus. Meanwhile, in a high profile trial failure, Pfizer discontinued development of its experimental oral weight-loss pill, danuglipron, following a case of potential drug-induced liver injury in a clinical trial participant. Another significant disappointment came from BMS’ investigational schizophrenia drug, Cobenfy (xanomeline and trospium chloride) — it failed to meet the primary endpoint in a pivotal late-stage trial evaluating its use as an adjunctive treatment for patients who no longer respond to standard antipsychotics. Adding to the month’s disappointments, FDA declined to approve Aldeyra Therapeutics’ dry eye disease treatment, reproxalap, for the second time.  Access the Pipeline Prospector Dashboard for April 2025 Newsmakers (Free Excel)  Amgen’s Uplizna, Sanofi’s Dupixent among noteworthy FDA approvals Amgen received a groundbreaking approval for Uplizna (inebilizumab-cdon) as the first and only treatment for immunoglobulin G4-related disease (IgG4-RD), a rare and chronic immune-mediated inflammatory condition. Analysts estimate that Uplizna could generate global annual sales of US$ 1.3 billion by 2030 for the IgG4-RD indication alone.  Sanofi and Regeneron received FDA approval for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in patients aged 12 and older who remain symptomatic despite antihistamine therapy. Sanofi’s bestselling drug is now FDA-approved for seven indications. As the month drew to a close, FDA approved Abeona Therapeutics’ gene therapy — Zevaskyn (prademagene zamikeracel) — for a rare skin disorder known as recessive dystrophic epidermolysis bullosa. It also approved Johnson & Johnson’s Imaavy (nipocalimab-aahu), a drug that treats patients aged 12 years and older with a form of generalized myasthenia gravis (gMG) — an immunity-related disorder that weakens the skeletal muscles, especially those in the eyes, mouth, throat and limbs.  Access the Pipeline Prospector Dashboard for April 2025 Newsmakers (Free Excel)  Our view The US economy contracted by 0.3 percent during the first quarter of 2025, as businesses panicked and imported goods to avoid higher costs. The US dollar has been weakening, and has hit a fresh low against the euro, Japanese yen and the Swiss franc. This will reduce the profit of foreign companies from their US divisions once they remit their earnings back to their home country. A study undertaken by Ernst & Young has predicted that a 25 percent US tariff on drug imports would increase drug cost by nearly US$ 51 billion annually, thereby boosting drug prices in America by 12.9 percent. These and other cues only point to the fact that Trump administration’s policies will hurt the US. As of today, a rollback or a softening of stand looks like a distant possibility. Access the Pipeline Prospector Dashboard for April 2025 Newsmakers (Free Excel)  

Impressions: 4625

https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-april-2025-merck-kgaa-buys-springwork-for-us-3-9-bn-swiss-giants-lead-pharma-migration-to-us-soil

#PharmaFlow by PHARMACOMPASS
01 May 2025

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 2212020-52-3 / Orforglipron Calcium Hydrate API manufacturers, exporters & distributors?

Orforglipron Calcium Hydrate manufacturers, exporters & distributors 1

33

PharmaCompass offers a list of Orforglipron Calcium Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier.

PharmaCompass also assists you with knowing the Orforglipron Calcium Hydrate API Price utilized in the formulation of products. Orforglipron Calcium Hydrate API Price is not always fixed or binding as the Orforglipron Calcium Hydrate Price is obtained through a variety of data sources. The Orforglipron Calcium Hydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Orforglipron Calcium Hydrate

Synonyms

2212020-52-3, Ly3502970, Chembl4446782, Ly-3502970, 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one, 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one

Cas Number

2212020-52-3

Unique Ingredient Identifier (UNII)

7ZW40D021M

Orforglipron Calcium Hydrate Manufacturers

A Orforglipron Calcium Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orforglipron Calcium Hydrate, including repackagers and relabelers. The FDA regulates Orforglipron Calcium Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orforglipron Calcium Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Orforglipron Calcium Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Orforglipron Calcium Hydrate Suppliers

A Orforglipron Calcium Hydrate supplier is an individual or a company that provides Orforglipron Calcium Hydrate active pharmaceutical ingredient (API) or Orforglipron Calcium Hydrate finished formulations upon request. The Orforglipron Calcium Hydrate suppliers may include Orforglipron Calcium Hydrate API manufacturers, exporters, distributors and traders.

click here to find a list of Orforglipron Calcium Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Orforglipron Calcium Hydrate USDMF

A Orforglipron Calcium Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Orforglipron Calcium Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Orforglipron Calcium Hydrate DMFs exist exist since differing nations have different regulations, such as Orforglipron Calcium Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Orforglipron Calcium Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Orforglipron Calcium Hydrate USDMF includes data on Orforglipron Calcium Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orforglipron Calcium Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Orforglipron Calcium Hydrate suppliers with USDMF on PharmaCompass.

Orforglipron Calcium Hydrate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Orforglipron Calcium Hydrate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Orforglipron Calcium Hydrate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Orforglipron Calcium Hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Orforglipron Calcium Hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Orforglipron Calcium Hydrate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Orforglipron Calcium Hydrate suppliers with NDC on PharmaCompass.

Orforglipron Calcium Hydrate GMP

Orforglipron Calcium Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Orforglipron Calcium Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Orforglipron Calcium Hydrate GMP manufacturer or Orforglipron Calcium Hydrate GMP API supplier for your needs.

Orforglipron Calcium Hydrate CoA

A Orforglipron Calcium Hydrate CoA (Certificate of Analysis) is a formal document that attests to Orforglipron Calcium Hydrate's compliance with Orforglipron Calcium Hydrate specifications and serves as a tool for batch-level quality control.

Orforglipron Calcium Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Orforglipron Calcium Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Orforglipron Calcium Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Orforglipron Calcium Hydrate EP), Orforglipron Calcium Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orforglipron Calcium Hydrate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty